The Medicines Company Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75% Convertible Senior Notes due 2023 (the “2023 Notes”) and (ii) 3.50% Convertible Senior Notes due 2024 (the “2024 Notes,” and collectively with the 2022 Notes and 2023 Notes, the “Notes”). The consummation of the previously announced transactions contemplated by the Agreement and Plan of Merger, dated as of November 23, 2019 (the “Merger Agreement”), by and among the Company, Novartis AG (the “Parent”) and Medusa Merger Corporation (“Merger Sub”), constitutes a Make-Whole Fundamental Change under: (i) the Indenture, dated as of January 13, 2015, governing the 2022 Notes (the “2022 Notes Indenture”), (ii) the Indenture, dated as of June 10, 2016, governing the 2023 Notes (the “2023 Notes Indenture”), and (iii) the Indenture, dated December 18, 2018, governing the 2024 Notes (the “2024 Notes Indenture,” and together with the 2022 Note Indenture and 2023 Notes Indenture, the “Indentures”). The Company also today provided notice to holders of the 2022 Notes that it will redeem all of the 2022 Notes on February 5, 2020, at a price of 100% of the principal amount of the 2022 Notes, plus accrued and unpaid interest.